Table 3.
Location and treatment of bone metastasis.
| Patient | Location of BM | Treatment of BM | Response to Treatment |
|---|---|---|---|
| A | Spine: T10-L3 | EBRT | PR, followed by progression and abdominopelvic metastasis at 9 months |
| B | R sacrum, T3, T11, L3 | Gemcitabine + bevacizumab | PR, currently receiving gemcitabine + bevacizumab |
| C | L acetabulum | Concurrent chemoradiation: EBRT + cisplatin, followed by carboplatin + paclitaxel | CR, currently under observation off therapy |
| D | R iliac & hemisacrum, L femoral neck | EBRT, followed by carboplatin + paclitaxel, followed by pembrolizumab | PR, currently receiving pembrolizumab |
| E | L iliac | EBRT | PR, followed by progression at 4 months |
| F | L iliac, T6 | EBRT | PD, with progression in the upper abdomen at 3 months |
| G | R iliac, L3-4 | PLD | SD, followed by progression in the bone and upper abdomen at 4 months |
| H | L iliac, T7-10, L1, L4, sternum | EBRT, followed by PLD | PR, followed by progression in the retroperitoneum at 5 months |
| I | T11 | EBRT, followed by carboplatin + paclitaxel | PR, currently receiving carboplatin + paclitaxel |
| J | L1, L3, R 7th rib | Pembrolizumab | SD, currently receiving pembrolizumab |
BM: Bone metastasis; CR: complete response; EBRT: External beam radiation therapy; PLD: pegylated liposomal doxorubicin; PD: progressive disease, PR: partial response; SD: stable disease.